The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock increased 8.04% or $0.2122 during the last trading session, reaching $2.8522. About 1.86M shares traded. InflaRx N.V. (NASDAQ:IFRX) has declined 90.11% since August 21, 2018 and is downtrending. It has underperformed by 90.11% the S&P500. Some Historical IFRX News: 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018The move comes after 5 months positive chart setup for the $74.06 million company. It was reported on Aug, 21 by Barchart.com. We have $3.05 PT which if reached, will make NASDAQ:IFRX worth $5.18 million more.
Among 8 analysts covering Laboratory Corp (NYSE:LH), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Laboratory Corp has $22000 highest and $164 lowest target. $184.38’s average target is 9.12% above currents $168.97 stock price. Laboratory Corp had 16 analyst reports since February 22, 2019 according to SRatingsIntel. The rating was maintained by Credit Suisse with “Outperform” on Wednesday, February 27. The company was maintained on Monday, March 18 by Barclays Capital. Citigroup maintained it with “Neutral” rating and $17600 target in Wednesday, May 1 report. The company was maintained on Friday, July 26 by Morgan Stanley. The stock of Laboratory Corporation of America Holdings (NYSE:LH) has “Buy” rating given on Friday, June 21 by Deutsche Bank. The stock of Laboratory Corporation of America Holdings (NYSE:LH) earned “Overweight” rating by KeyBanc Capital Markets on Thursday, August 8. On Friday, February 22 the stock rating was maintained by Morgan Stanley with “Buy”. The stock of Laboratory Corporation of America Holdings (NYSE:LH) has “Buy” rating given on Wednesday, May 1 by UBS. The firm has “Hold” rating given on Thursday, May 2 by Canaccord Genuity. KeyBanc Capital Markets maintained the shares of LH in report on Friday, March 15 with “Buy” rating. See Laboratory Corporation of America Holdings (NYSE:LH) latest ratings:
08/08/2019 Broker: KeyBanc Capital Markets Rating: Overweight Old Target: $172.0000 New Target: $192.0000 Maintain
26/07/2019 Broker: Morgan Stanley Rating: Overweight Old Target: $175.0000 New Target: $190.0000 Maintain
16/07/2019 Broker: Bank of America Old Rating: Underperform New Rating: Neutral Upgrade
21/06/2019 Broker: Deutsche Bank Old Rating: Hold New Rating: Buy Old Target: $180.0000 New Target: $220.0000 Upgrade
30/05/2019 Broker: BidaskScore Rating: Buy Upgrade
03/05/2019 Broker: BidaskScore Rating: Buy Upgrade
02/05/2019 Broker: Canaccord Genuity Old Rating: Hold New Rating: Hold Old Target: $155.0000 New Target: $165.0000 Maintain
01/05/2019 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $157.0000 New Target: $176.0000 Maintain
01/05/2019 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $178.0000 New Target: $195.0000 Maintain
17/04/2019 Broker: BidaskScore Rating: Hold Downgrade
Laboratory Corporation of America Holdings operates as an independent clinical laboratory firm worldwide. The company has market cap of $16.51 billion. It operates through two divisions, LabCorp Diagnostics and Covance Drug Development. It has a 19.93 P/E ratio. The firm offers a range of clinical laboratory tests and procedures, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, tests for sexually-transmitted diseases, HCV tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.
More notable recent Laboratory Corporation of America Holdings (NYSE:LH) news were published by: Finance.Yahoo.com which released: “Is Laboratory Corporation of America Holdings (NYSE:LH) Potentially Undervalued? – Yahoo Finance” on August 13, 2019, also Seekingalpha.com with their article: “Q2 2019 Hedge Fund Trends – Seeking Alpha” published on August 21, 2019, Seekingalpha.com published: “Laboratory Corporation of America EPS beats by $0.01, misses on revenue – Seeking Alpha” on July 25, 2019. More interesting news about Laboratory Corporation of America Holdings (NYSE:LH) were released by: Benzinga.com and their article: “Earnings Scheduled For July 25, 2019 – Benzinga” published on July 25, 2019 as well as Finance.Yahoo.com‘s news article titled: “If You Had Bought Laboratory of America Holdings (NYSE:LH) Shares Five Years Ago You’d Have Made 62% – Yahoo Finance” with publication date: June 05, 2019.
Investors sentiment increased to 1.06 in Q1 2019. Its up 0.25, from 0.81 in 2018Q4. It increased, as 58 investors sold Laboratory Corporation of America Holdings shares while 204 reduced holdings. 73 funds opened positions while 204 raised stakes. 87.65 million shares or 0.73% less from 88.30 million shares in 2018Q4 were reported. 7,637 were accumulated by Neuberger Berman Gru Llc. Blackrock accumulated 0.07% or 10.03 million shares. State Of Alaska Department Of Revenue invested in 68,761 shares. Golub Ltd holds 4.05% or 304,713 shares. Proshare Advsrs Ltd holds 15,426 shares or 0.01% of its portfolio. Allen Investment Management Ltd Company reported 955,887 shares. Speece Thorson Cap accumulated 3.53% or 83,881 shares. Paradigm Asset Co Limited Company owns 1,100 shares. Robeco Institutional Asset Mngmt Bv holds 25,580 shares or 0.01% of its portfolio. Chilton Cap Mgmt Limited Liability invested 0.05% in Laboratory Corporation of America Holdings (NYSE:LH). Archford Strategies Ltd Company holds 38 shares. Rocky Mountain Advisers Limited reported 0.01% of its portfolio in Laboratory Corporation of America Holdings (NYSE:LH). State Of Tennessee Treasury Department holds 0.02% or 24,672 shares. Hallmark Mngmt reported 101,920 shares or 1.7% of all its holdings. Camelot Portfolios Limited has invested 0.11% in Laboratory Corporation of America Holdings (NYSE:LH).
The stock increased 1.17% or $1.96 during the last trading session, reaching $168.97. About 118,528 shares traded. Laboratory Corporation of America Holdings (NYSE:LH) has declined 2.94% since August 21, 2018 and is downtrending. It has underperformed by 2.94% the S&P500. Some Historical LH News: 24/04/2018 – LABCORP SAYS CO, MOUNT SINAI ENTERED INTO CONTRACT THAT WILL “ENHANCE” LAB OPERATIONS AT EACH OF MOUNT SINAI’S 7 ACUTE CARE HOSPITALS – SEC FILING; 23/04/2018 – DJ Laboratory Corporation of America H, Inst Holders, 1Q 2018 (LH); 20/03/2018 – INTERPACE DIAGNOSTICS – UNDER NEW AGREEMENT, PHYSICIANS WILL BE ABLE TO ORDER BOTH THYROID BIOPSY ANALYSIS AND MOLECULAR TESTING FROM INTERPACE; 21/03/2018 – Report: Developing Opportunities within Roper Technologies, Basic Energy Services, Laboratory Corporation of America, Brown For; 25/04/2018 – LABORATORY CORP OF AMERICA BOOSTS VIEW FOR YEAR SALES GROWTH; 25/04/2018 – LABCORP – EFFECTIVE JANUARY 1, 2018, COMPANY ADOPTED FASB-ISSUED CONVERGED STANDARD ON REVENUE RECOGNITION (ASC 606); 25/04/2018 – Labcorp Closes Above 50-Day Moving Average: Technicals; 24/04/2018 – LABCORP – CO, MOUNT SINAI HEALTH SYSTEM HAVE BEGUN IMPLEMENTING PROGRAM TO STANDARDIZE & OPTIMIZE INPATIENT LAB SERVICES ACROSS MOUNT SINAI SYSTEM; 01/05/2018 – Moody’s: Labcorp’s Divestiture Of Food Solutions Business Is Credit Positive; 09/03/2018 – Covance Forms lmmunology & lmmunotoxicology Unit Focused on Biologic Drug Development
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $74.06 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.